Seres therapeutics presents phase ill results of ser-109 for recurrent c. difficile infection at the digestive disease week (ddw) annual meeting

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome company, today announced the presentation of data from its phase 3 ecospor iii study that suggest investigational microbiome-based therapeutic ser-109 prevents recurrent c. difficile infections (rcdi) by rapidly establishing a long-lasting colony of beneficial gut microbes, which can produce fatty acids that disrupt the c. difficile lifecycle. these data were shared in oral and poster presentations
MCRB Ratings Summary
MCRB Quant Ranking